- Home
- JXJT vs LSBPW Comparison
JXJT vs LSBPW Comparison
Compare JXJT & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXJT
- LSBPW
- Stock Information
- Founded
- JXJT 2012
- LSBPW N/A
- Country
- JXJT China
- LSBPW China
- Employees
- JXJT N/A
- LSBPW 758
- Industry
- JXJT Apparel
- LSBPW Biotechnology: Pharmaceutical Preparations
- Sector
- JXJT Consumer Staples
- LSBPW Health Care
- Exchange
- JXJT Nasdaq
- LSBPW Nasdaq
- Market Cap
- JXJT 11.5M
- LSBPW N/A
- IPO Year
- JXJT 2012
- LSBPW N/A
- Fundamental
- Price
- JXJT $1.57
- LSBPW $0.07
- Analyst Decision
- JXJT
- LSBPW
- Analyst Count
- JXJT 0
- LSBPW 0
- Target Price
- JXJT N/A
- LSBPW N/A
- AVG Volume (30 Days)
- JXJT 36.7K
- LSBPW N/A
- Earning Date
- JXJT 11-01-2024
- LSBPW N/A
- Dividend Yield
- JXJT N/A
- LSBPW N/A
- EPS Growth
- JXJT N/A
- LSBPW N/A
- EPS
- JXJT 0.48
- LSBPW N/A
- Revenue
- JXJT $31,840,588.00
- LSBPW N/A
- Revenue This Year
- JXJT N/A
- LSBPW N/A
- Revenue Next Year
- JXJT N/A
- LSBPW N/A
- P/E Ratio
- JXJT $3.40
- LSBPW N/A
- Revenue Growth
- JXJT N/A
- LSBPW N/A
- 52 Week Low
- JXJT $1.04
- LSBPW N/A
- 52 Week High
- JXJT $8.51
- LSBPW N/A
- Technical
- Relative Strength Index (RSI)
- JXJT 38.73
- LSBPW N/A
- Support Level
- JXJT $1.40
- LSBPW N/A
- Resistance Level
- JXJT $1.75
- LSBPW N/A
- Average True Range (ATR)
- JXJT 0.14
- LSBPW 0.00
- MACD
- JXJT -0.04
- LSBPW 0.00
- Stochastic Oscillator
- JXJT 32.08
- LSBPW 0.00
About JXJT JX Luxventure Limited
JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About LSBPW LakeShore Biopharma Co. Ltd
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.